Article Text

Download PDFPDF

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
  1. Ashish M. Kamat1,a,
  2. Joaquim Bellmunt2,
  3. Matthew D. Galsky3,
  4. Badrinath R. Konety4,
  5. Donald L. Lamm5,
  6. David Langham6,
  7. Cheryl T. Lee7,
  8. Matthew I. Milowsky8,
  9. Michael A. O’Donnell9,
  10. Peter H. O’Donnell10,
  11. Daniel P. Petrylak11,
  12. Padmanee Sharma12,
  13. Eila C. Skinner13,
  14. Guru Sonpavde14,
  15. John A. Taylor III15,
  16. Prasanth Abraham16 and
  17. Jonathan E. Rosenberg17
  1. Aff1 0000 0001 2291 4776grid.240145.6University of Texas MD Anderson Cancer Center 1515 Pressler Unit 1373 77030 Houston TX USA
  2. Aff2 0000 0001 2106 9910grid.65499.37Dana-Farber Cancer Institute 02446 Brookline MA USA
  3. Aff3 grid.416167.3Tisch Cancer Institute at Mount Sinai Medical Center 10029 New York NY USA
  4. Aff4 0000000419368657grid.17635.36University of Minnesota 55455 Minneapolis MN USA
  5. Aff5 BCG Oncology 85032 Phoenix AZ USA
  6. Aff6 grid.473769.8Bladder Cancer Advocacy Network, North Carolina Triangle Chapter 27517 Chapel Hill NC USA
  7. Aff7 0000 0001 1545 0811grid.412332.5The Ohio State University Wexner Medical Center 43210 Columbus OH USA
  8. Aff8 0000 0001 1034 1720grid.410711.2University of North Carolina 27599 Chapel Hill NC USA
  9. Aff9 0000 0004 1936 8294grid.214572.7University of Iowa 52242 Iowa City IA USA
  10. Aff10 0000 0004 1936 7822grid.170205.1University of Chicago 60637 Chicago IL USA
  11. Aff11 grid.433818.5Yale Cancer Center 06520 New Haven CT USA
  12. Aff12 0000 0001 2291 4776grid.240145.6University of Texas MD Anderson Cancer Center 77030 Houston TX USA
  13. Aff13 0000000419368956grid.168010.eStanford University 94305 Stanford CA USA
  14. Aff14 0000000106344187grid.265892.2University of Alabama 35294 Birmingham AL USA
  15. Aff15 0000 0004 0408 2680grid.468219.0University of Kansas Cancer Center 66160 Kansas City KS USA
  16. Aff16 0000 0001 2291 4776grid.240145.6University of Texas MD Anderson Cancer Center 77030 Houston TX USA
  17. Aff17 0000 0001 2171 9952grid.51462.34Memorial Sloan Kettering Cancer Center 10065 New York NY USA
  1. a akamat{at}
  • The online version of the original article can be found under doi:10.1186/s40425-017-0271-0

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


After the publication of the article [1], the treatment algorithm for advanced/metastatic bladder cancer in Fig. 3 was updated to reflect the current use of immunotherapy in this setting. The correct Fig. 3 can be seen here and the original article has been updated to reflect this change.

Fig. 3

All of the treatment options shown may be appropriate. The selection of therapy should be individualized based on patient eligibility and the availability of therapy, at the discretion of the treating physician. These algorithms represent the consensus recommendations of the Task Force. (1) Atezolizumab and pembrolizumab are FDA approved for patients with metastatic urothelial carcinoma who are ineligible to receive cisplatin. (2) Atezolizumab, nivolumab, durvalumab, avelumab, and pembrolizumab are FDA approved for advanced disease that has worsened on platinum containing regimens or within 12 months of receiving a platinum-containing regimen before (neoadjuvant) or after surgery (adjuvant). Abbreviations: dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DDMVAC)


  1. 1.